Elizabeth Mittendorf, M.D., Ph.D.

Dr. Mittendorf is Associate Professor in the Department of Breast Surgical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Mittendorf has focused both her clinical and laboratory efforts on the study of breast cancer, specifically on breast cancer immunotherapy. She is the Principal Investigator of several breast cancer vaccine trials including the Phase III PRESENT clinical trial, a multicenter Phase II trial that investigates the efficacy of two additional HER2-derived peptide vaccines. Furthermore, she is the PI of a Phase I trial that evaluates combination immunotherapy with vaccines and trastuzumab, an FDA-approved antibody used to treat breast cancer. Her laboratory research is focused on identifying novel tumor antigens that can be used as targets for vaccination. In addition, her research group studies the link between innate immunity and adaptive immune responses in the tumor microenvironment.

Dr. Mittendorf serves as the CITO’s Senior Cancer Clinical Translation Investigator, an Administrative Core Co-Leader, and Co-Leader of Project 1 with Dr. Shen and Dr. Wang.